IHC - CD 25

The test is performed on a tissue sample, typically obtained through a biopsy. The sample is processed in a lab, where it's stained with a dye that binds to the CD25 protein, if present.

Any risks associated with this test are primarily related to the biopsy procedure used to obtain the tissue sample. These risks might include pain, infection, or bleeding at the biopsy site.

A positive result indicates that the CD25 protein is present in the tissue sample, which might suggest a certain type of lymphoma or leukemia.

A negative result means the CD25 protein was not detected in the tissue sample. This can help rule out certain types of lymphomas and leukemias.

The turnaround time for the test is usually 7 to 10 days, although this can vary depending on the laboratory.

If you get a positive result, your healthcare provider will discuss next steps with you, which might include further testing or treatment options.

Yes, there are no dietary restrictions before this test.

The IHC - CD 25 test is primarily used in the context of certain lymphomas and leukemias. However, CD25 is also expressed in various immune response scenarios and its role in other diseases is an active area of research.

Insurance coverage for this test can vary, so you'll need to check with your insurance provider to determine if this test is covered.

No specific preparation is needed for this test.

No, this test requires a tissue sample that must be collected and processed in a laboratory setting.

The test itself is not painful. However, the biopsy procedure to collect the tissue sample can cause some discomfort.

The quality of the tissue sample and the handling and processing of the sample can potentially impact the test results.

There is no specific age limit for this test. It can be performed based on the clinical necessity and the healthcare provider's judgment.

The IHC - CD 25 test is considered a reliable method for identifying the CD25 protein. However, it's crucial to remember that no test is 100% accurate. Test results should always be considered in the context of other clinical information and diagnostic tests.

This test can be performed during pregnancy if clinically necessary. Any potential risks or considerations will be discussed by your healthcare provider.

This test requires a tissue sample, generally obtained via a biopsy.

Yes, the results of this test can assist healthcare providers in determining the best course of treatment by providing information about the presence or absence of the CD25 protein, which is implicated in certain types of blood cancers.